TITLE

Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures

AUTHOR(S)
Taddio, Anna; Shah, Vibhuti; Hancock, Rebecca; Smith, Ryan W.; Stephens, Derek; Atenafu,7, Eshetu; Beyene, Joseph; Koren, Gideon; Stevens, Bonnie; Katz, Joel
PUB. DATE
July 2008
SOURCE
CMAJ: Canadian Medical Association Journal;7/1/2008, Vol. 179 Issue 1, p37
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Background: Sucrose is widely used to manage procedural pain in term newborns despite a lack of evidence of its effectiveness for different procedures and infant populations. Our objectives were to evaluate the effectiveness and safety of sucrose in newborns undergoing various medical procedures within 2 days of birth. Methods: We performed a double-blind, randomized controlled trial. We included newborns (= 36 weeks gestation) of diabetic mothers and nondiabetic mothers. Each newborn received 2 mL of a 24%-sucrose or placebo solution before all procedures. We used the Premature Infant Pain Profile to assess pain during intramuscular injection of vitamin K, venipuncture for the newborn screening test and the first 3 heel lances for glucose monitoring (newborns of diabetic mothers only). Scores ranged from from 0 (no pain) to 18 (maximum pain). Results: We included 240 newborns (120 from diabetic mothers, 120 from nondiabetic mothers). The overall mean pain score was lower among newborns who received sucrose than among those who received a placebo (mean difference -1.3, 95% confidence interval [CI] -2.0 to -0.6). We found that pain scores during intramuscular injection did not differ significantly between the sucrose and placebo groups for newborns of diabetic or nondiabetic mothers (newborns of nondiabetic mothers: mean difference -1.1, 95% CI -2.4 to 0.2; newborns of diabetic mothers: mean difference -1.0, 95% CI -2.4 to 0.4). During venipuncture, newborns who received sucrose had lower pain scores compared with those who received a placebo (newborns of nondiabetic mothers: mean difference -3.2, 95% CI -4.6 to -1.8; newborns of diabetic mothers: mean difference -2.4, 95% CI -3.8 to -1.0). Among newborns of diabetic mothers, there was no difference in pain during the first 3 heel lances or mean glucose levels between the sucrose and placebo groups (p = 0.94 and p = 0.29 respectively). Interpretation: We found a modest reduction of pain in newborns of both diabetic and nondiabetic mothers when sucrose was used for all medical procedures performed in the first 2 days after birth. However, when each procedure was analyzed separately, we found that the effectiveness of sucrose was limited to venipuncture for the newborn screening test.
ACCESSION #
32678891

 

Related Articles

  • The effect of vapocoolant spray on pain due to intravenous cannulation in children: a randomized controlled trial. Farion, Ken J.; Splinter, Karen L.; Newhook, Kym; Gaboury, Isabelle; Splinter, William M. // CMAJ: Canadian Medical Association Journal;7/1/2008, Vol. 179 Issue 1, p31 

    Background: Established noninvasive pharmacologic means of alleviating pain and anxiety in children undergoing intravenous cannulation are time-consuming, and thus impractical for routine use in the emergency department. Vapocoolant sprays provide transient skin anesthesia within seconds of...

  • A spoonful of sugar helps children's vaccination go down.  // Nursing Standard;4/16/2008, Vol. 22 Issue 32, p17 

    The article evaluates the analgesic effects of oral sucrose during routine immunisations of two and four months old infants. Researchers undertook a prospective, randomised. placebo-controlled trial involving 100 healthy infants scheduled for routine immunisations. It was found that infants aged...

  • Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. Yenrudee Poomtavorn; Vorapong Phupong // Archives of Gynecology & Obstetrics;Dec2005, Vol. 273 Issue 2, p115 

    Objective: To evaluate the analgesic efficacy of preoperative rofecoxib in patients who underwent uterine curettage. Materials and methods: This double-blinded, randomized, placebo-controlled trial included 80 women who underwent uterine curettage. Forty women were randomly assigned to rofecoxib...

  • Janssen announces encouraging results from Phase III DPN study.  // PharmaWatch: CNS;Jul2012, Vol. 11 Issue 7, p37 

    The article reports on the announcement of Janssen Pharmaceuticals Inc. on the results of a Phase III study for diabetic peripheral neuropathy (DPN) treatment. It suggests that Nucynta Er or tapentadol tablets were more effective than placebo in providing pain management among adults with...

  • Concept Proven: Array Hits Analgesic Endpoint in Phase II. Shaffer, Catherine // BioWorld Today;8/2/2012, Vol. 23 Issue 149, p1 

    The article reports that the p38-alpha kinase inhibitor ARRY-797 of Array BioPharma Inc. has hit its primary endpoint of reducing pain more than placebo in a Phase II proof-of-concept trial. The trial involved 157 patients afflicted with moderate-to-severe pain in spite of the use of...

  • Flecainide for the treatment of chronic neuropathic pain: a Phase II trial: Eastern Co-operative Oncology Group Study E1Z95. von Gunten, Charles F.; Eappen, Sarah; Cleary, James Francis; Taylor IV, Samuel G.; Moots, Paul; Regevik, Nina; Cleeland, Charles; Cella, David // Palliative Medicine;Dec2007, Vol. 21 Issue 8, p667 

    Background: Management of neuropathic pain is challenging. Medications that interfere with sodium channel transport, such as lidocaine, mexilitene and flecainide, are promising as analgesics. Objective: In a general population of patients with a working diagnosis of neuropathic pain, whether if...

  • PARAVERTEBRAL ROPIVACAINE 0.5 PERCENT VERSUS SALINE INFILTRATION ON POSTOPERATIVE PAIN SCORES AND REQUIREMENT OF RESCUE ANALGESIC. Bhat, Imran; Ganie, Farooq Ahmad; Velayat, Buch; Maqbool, Asif; Farooqi, Ayaz // Journal of Pharmaceutical & Scientific Innovation;Jul/Aug2013, Vol. 2 Issue 4, p82 

    This study was designed to determine whether ropivacane decreases the severity of acute post-thoracotomy pain scores and whether ropivacane decreases the dosage and need of rescue analgesics in comparison with placebo. In our study Patients were randomly assigned in a blinded fashion to receive...

  • BEWARE STATISTICAL OUTPUTS.  // Bandolier;Sep2006, Vol. 13 Issue 9, p4 

    The article focuses on a scientific study which reveals that the relative benefit of using placebo varies depending on the kind of clinical procedures. The relative benefit varies from 31% at 1% placebo response to 1.5% at 61% placebo response. The study reveals that the efficacy of using...

  • Reduction in Opioid-Related Adverse Events and Improvement in Function with Parecoxib followed by Valdecoxib Treatment after Non-Cardiac Surgery. Langford, Richard M.; Joshi, Girish P.; Gan, Tong J.; Mattera, Maria Stoeckl; Wen-Hung Chen; Revicki, Dennis A.; Chen, Connie; Zlateva, Gergana // Clinical Drug Investigation;2009, Vol. 29 Issue 9, p577 

    Background: Multimodal pain therapy including cyclo-oxygenase-2 inhibitors can result in optimal pain management with decreased opioid use and fewer opioid-related adverse events. Patient reported outcomes (PROs) help identify benefits in reduced opioid use and increased pain control. Methods:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics